Warning: Undefined array key 0 in /www/ipwatchdogcom_574/public/wp-includes/class-wp-query.php on line 3571

Jim Greenwood


Warning: Undefined variable $args in /www/ipwatchdogcom_574/public/wp-content/themes/ipwatchdog/parts/people/authored-posts.php on line 2

Recent Articles by

BIO Hails House Passage of FDA Safety and Innovation Act

It will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase FDA’s access to external expertise to improve the drug review process. FDASIA will foster timely interactive communication with sponsors during the drug development phase as a core Agency activity to facilitate the conduct of efficient and effective drug development programs and help make safe and effective drugs available to the American public in a timely manner.

House Patent Reform Bill is in Need of Reform, BIO to Oppose

BIO has consistently praised House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a comprehensive patent reform bill similar to the bill adopted by the U.S. Senate earlier this month by a nearly unanimous vote. Unfortunately, given the addition of the Goodlatte supplemental examination amendment, added to the bill during Committee consideration, we have no choice but to oppose floor consideration of the bill until this issue is repaired.

BIO Expresses Some Concern with House Patent Reform

BIO also is concerned about the inclusion of broader prior user rights in the House bill, and believes that this issue, coupled with the harmful inter partes review changes, could set back efforts to pass meaningful patent reform this year by undermining the broad coalition of American innovators currently supporting patent reform.